John M. Inadomi, MD

Department Chair, Department of Internal Medicine

Languages

  • English

Academic Information

  • Departments: Internal Medicine - Professor
  • Divisions: Gastroenterology

Board Certification

  • American Board of Internal Medicine (Internal Medicine)
  • American Board of Internal Medicine (Sub: Gastroenterology)

Education History

Type School Degree
Fellowship University of California, San Francisco
Gastroenterology
Fellow
Residency University of California, San Francisco
Internal Medicine
Resident
Internship University of California, San Francisco
Internal Medicine
Intern
Professional Medical University of California, San Francisco
Medicine
M.D.
Undergraduate Massachusetts Institute of Technology
Mechanical Engineering
S.B.

Selected Publications

Journal Article

  1. Inadomi JM, Issaka RB, Green BB (2019). What Multi-Level Interventions Do We Need to Increase the Colorectal Cancer Screening Rate to 80%? (Epub ahead of print) Clin Gastroenterol Hepatol.
  2. Omidvari AH, Ali A, Hazelton WD, Kroep S, Lee M, Naber SK, Lauren BN, Ostvar S, Richmond E, Kong CY, Rubenstein JH, Lansdorp-Vogelaar I, Luebeck G, Hur C, Inadomi J (2019). Optimizing Management of Patients with Barrett's Esophagus and Low-grade or No Dysplasia Based On Comparative Modeling: Optimizing Barrett's esophagus management. (Epub ahead of print) Clin Gastroenterol Hepatol.
  3. Burnett-Hartman AN, Kamineni A, Corley DA, Singal AG, Halm EA, Rutter CM, Chubak J, Lee JK, Doubeni CA, Inadomi JM, Doria-Rose VP, Zheng Y (2019). Colonoscopy Indication Algorithm Performance Across Diverse Health Care Systems in the PROSPR Consortium. EGEMS (Wash DC), 7(1), 37.
  4. Rastogi N, Xia Y, Inadomi JM, Kwon SC, Trinh-Shevrin C, Liang PS (2019). Disparities in colorectal cancer screening in New York City: An analysis of the 2014 NYC Community Health Survey. Cancer Med, 8(5), 2572-2579.
  5. Luebeck GE, Hazelton WD, Curtius K, Maden SK, Yu M, Carter KT, Burke W, Lampe PD, Li CI, Ulrich CM, Newcomb PA, Westerhoff M, Kaz AM, Luo Y, Inadomi JM, Grady WM (2018). Implications of Epigenetic Drift in Colorectal Neoplasia. Cancer Res, 79(3), 495-504.
  6. Issaka RB, Inadomi JM (2018). Low-Value Colorectal Cancer Screening: Too Much of a Good Thing? JAMA Netw Open, 1(8), e185445.
  7. Inadomi JM, Saxena N (2018). Endoscopic surveillance or ablation for Barrett's esophagus? Transl Gastroenterol Hepatol, 3, 102.
  8. Inadomi J, Alastal H, Bonavina L, Gross S, Hunt RH, Mashimo H, di Pietro M, Rhee H, Shah M, Tolone S, Wang DH, Xie SH (2018). Recent advances in Barrett's esophagus. Ann N Y Acad Sci, 1434(1), 227-238.
  9. Inadomi JM, Saxena N (2018). Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective? Dig Dis Sci, 63(8), 2094-2104.
  10. Codipilly DC, Chandar AK, Singh S, Wani S, Shaheen NJ, Inadomi JM, Chak A, Iyer PG (2018). The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis. Gastroenterology, 154(8), 2068-2086.e5.
  11. Choi AY, Strate LL, Fix MC, Schmidt RA, Ende AR, Yeh MM, Inadomi JM, Hwang JH (2017). Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a U.S. population. Gastrointest Endosc, 87(4), 1023-1028.
  12. Chu JN, Choi J, Tramontano A, Morse C, Forcione D, Nishioka NS, Abrams JA, Rubenstein JH, Kong CY, Inadomi JM, Hur C (2017). Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. Clin Gastroenterol Hepatol, 16(3), 392-400.e7.
  13. Ende AR, De Groen P, Balmadrid BL, Hwang JH, Inadomi J, Wojtera T, Egorov V, Sarvazyan N, Korman L (2017). Objective Differences in Colonoscopy Technique Between Trainee and Expert Endoscopists Using the Colonoscopy Force Monitor. Dig Dis Sci, 63(1), 46-52.
  14. Rubenstein JH, Pohl H, Adams MA, Kerr E, Holleman R, Vijan S, Dominitz JA, Inadomi JM, Provenzale D, Francis J, Saini SD (2017). Overuse of Repeat Upper Endoscopy in the Veterans Health Administration: A Retrospective Analysis. Am J Gastroenterol, 112(11), 1678-1685.
  15. Kroep S, Heberle CR, Curtius K, Kong CY, Lansdorp-Vogelaar I, Ali A, Wolf WA, Shaheen NJ, Spechler SJ, Rubenstein JH, Nishioka NS, Meltzer SJ, Hazelton WD, van Ballegooijen M, Tramontano AC, Gazelle GS, Luebeck EG, Inadomi JM, Hur C (2017). Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. Clin Gastroenterol Hepatol, 15(9), 1471-1474.
  16. Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC, Dowling EC, Hazelton WD, Luebeck EG, Lansdorp-Vogelaar I, Hur C (2017). Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. Clin Gastroenterol Hepatol, 15(9), 1397-1404.e7.
  17. Ritvo P, Myers RE, Serenity M, Gupta S, Inadomi JM, Green BB, Jerant A, Tinmouth J, Paszat L, Pirbaglou M, Rabeneck L (2016). Taxonomy for colorectal cancer screening promotion: Lessons from recent randomized controlled trials. Prev Med, 101, 229-234.
  18. Tramontano AC, Sheehan DF, Yeh JM, Kong CY, Dowling EC, Rubenstein JH, Abrams JA, Inadomi JM, Schrag D, Hur C (2017). The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. Am J Gastroenterol, 112(8), 1256-1264.
  19. Wani S, Muthusamy VR, Shaheen NJ, Yadlapati R, Wilson R, Abrams JA, Bergman J, Chak A, Chang K, Das A, Dumot J, Edmundowicz SA, Eisen G, Falk GW, Fennerty MB, Gerson L, Ginsberg GG, Grande D, Hall M, Harnke B, Inadomi J, Jankowski J, Lightdale CJ, Makker J, Odze RD, Pech O, Sampliner RE, Spechler S, Triadafilopoulos G, Wallace MB, Wang K, Waxman I, Komanduri S (2017). Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Am J Gastroenterol, 112(7), 1032-1048.
  20. Saxena N, Inadomi JM (2017). Effectiveness and Cost-Effectiveness of Endoscopic Screening and Surveillance. Gastrointest Endosc Clin N Am, 27(3), 397-421.
  21. Johnson DA, Lieberman D, Inadomi JM, Ladabaum U, Becker RC, Gross SA, Hood KL, Kushins S, Pochapin M, Robertson DJ (2016). Increased Post-procedural Non-gastrointestinal Adverse Events After Outpatient Colonoscopy in High-risk Patients. Clin Gastroenterol Hepatol, 15(6), 883-891.e9.
  22. ASGE Endoscopy Unit Quality Indicator Taskforce, Day LW, Cohen J, Greenwald D, Petersen BT, Schlossberg NS, Vicari JJ, Calderwood AH, Chapman FJ, Cohen LB, Eisen G, Gerstenberger PD, Hambrick RD 3rd, Inadomi JM, MacIntosh D, Sewell JL, Valori R (2017). Quality indicators for gastrointestinal endoscopy units. VideoGIE, 2(6), 119-140.
  23. Inadomi JM (2017). Screening for Colorectal Neoplasia. N Engl J Med, 376(2), 149-156.
  24. Ko LK, Taylor VM, Yoon J, Copeland WK, Hwang JH, Lee EJ, Inadomi J (2016). The impact of medical tourism on colorectal screening among Korean Americans: A community-based cross-sectional study. BMC Cancer, 16(1), 931.
  25. Lieberman D, Ladabaum U, Cruz-Correa M, Ginsburg C, Inadomi JM, Kim LS, Giardiello FM, Wender RC (2016). Screening for Colorectal Cancer and Evolving Issues for Physicians and Patients: A Review. JAMA, 316(20), 2135-2145.
  26. Burnett-Hartman AN, Mehta SJ, Zheng Y, Ghai NR, McLerran DF, Chubak J, Quinn VP, Skinner CS, Corley DA, Inadomi JM, Doubeni CA, PROSPR Consortium (2016). Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. Am J Prev Med, 51(4), e107-15.
  27. Horibe M, Kaneko T, Yokogawa N, Yokota T, Okawa O, Nakatani Y, Ogura Y, Matsuzaki J, Iwasaki E, Hosoe N, Masaoka T, Inadomi JM, Suzuki H, Kanai T, Namiki S (2016). A simple scoring system to assess the need for an endoscopic intervention in suspected upper gastrointestinal bleeding: A prospective cohort study. Dig Liver Dis, 48(10), 1180-6.
  28. Katzka DA, Friedman LS, Inadomi JM, Kalloo AM, Kim LS, Koch J, Lieberman D, Lichtenstein GR, Lim JK, Pandolfino JE, Shin AS, Siedler MR (2016). Introduction to Clinical Practice Update Committee Articles. Gastroenterology, 151(1), 45.
  29. Wernli KJ, Brenner AT, Rutter CM, Inadomi JM (2015). Risks Associated With Anesthesia Services During Colonoscopy. Gastroenterology, 150(4), 888-94; quiz e18.
  30. Liang PS, Wheat CL, Abhat A, Brenner AT, Fagerlin A, Hayward RA, Thomas JP, Vijan S, Inadomi JM (2015). Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years. Am J Gastroenterol, 111(1), 105-14.
  31. Brenner AT, Gupta S, Ko LK, Janz N, Inadomi JM (2016). Development of a Practical Model for Targeting Patient Decision Support Interventions to Promote Colorectal Cancer Screening in Vulnerable Populations. J Health Care Poor Underserved, 27(2), 465-78.
  32. Sharma P, Katzka DA, Gupta N, Ajani J, Buttar N, Chak A, Corley D, El-Serag H, Falk GW, Fitzgerald R, Goldblum J, Gress F, Ilson DH, Inadomi JM, Kuipers EJ, Lynch JP, McKeon F, Metz D, Pasricha PJ, Pech O, Peek R, Peters JH, Repici A, Seewald S, Shaheen NJ, Souza RF, Spechler SJ, Vennalaganti P, Wang K (2015). Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology, 149(6), 1599-606.
  33. Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, de Koning HJ, Meester R, Inadomi JM, van Ballegooijen M (2015). An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling. Gastroenterology, 149(3), 577-85.e4; quiz e14-5.
  34. Shergill AK, Conners EE, McQuaid KR, Epstein S, Ryan JC, Shah JN, Inadomi J, Somsouk M (2015). Protective association of colonoscopy against proximal and distal colon cancer and patterns in interval cancer. Gastrointest Endosc, 82(3), 529-37.e1.
  35. Kroep S, Lansdorp-Vogelaar I, van der Steen A, Inadomi JM, van Ballegooijen M (2014). The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions. Med Decis Making, 35(6), 726-33.
  36. Brenner AT, Ko LK, Janz N, Gupta S, Inadomi J (2015). Race/Ethnicity and Primary Language: Health Beliefs about Colorectal Cancer Screening in a Diverse, Low-Income Population. J Health Care Poor Underserved, 26(3), 824-38.
  37. Matsuzaki J, Suzuki H, Kobayakawa M, Inadomi JM, Takayama M, Makino K, Iwao Y, Sugino Y, Kanai T (2015). Association of Visceral Fat Area, Smoking, and Alcohol Consumption with Reflux Esophagitis and Barrett's Esophagus in Japan. PLoS ONE, 10(7), e0133865.
  38. Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, Hur C, Luebeck EG (2015). The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev, 24(7), 1012-23.
  39. Senore C, Inadomi J, Segnan N, Bellisario C, Hassan C (2015). Optimising colorectal cancer screening acceptance: a review. Gut, 64(7), 1158-77.
  40. Bennett C, Moayyedi P, Corley DA, DeCaestecker J, Falck-Ytter Y, Falk G, Vakil N, Sanders S, Vieth M, Inadomi J, Aldulaimi D, Ho KY, Odze R, Meltzer SJ, Quigley E, Gittens S, Watson P, Zaninotto G, Iyer PG, Alexandre L, Ang Y, Callaghan J, Harrison R, Singh R, Bhandari P, Bisschops R, Geramizadeh B, Kaye P, Krishnadath S, Fennerty MB, Manner H, Nason KS, Pech O, Konda V, Ragunath K, Rahman I, Romero Y, Sampliner R, Siersema PD, Tack J, Tham TC, Trudgill N, Weinberg DS, Wang J, Wang K, Wong JY, Attwood S, Malfertheiner P, MacDonald D, Barr H, Ferguson MK, Jankowski J, BOB CAT Consortium (2015). BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol, 110(5), 662-82; quiz 683.
  41. Elmunzer BJ, Singal AG, Sussman JB, Deshpande AR, Sussman DA, Conte ML, Dwamena BA, Rogers MA, Schoenfeld PS, Inadomi JM, Saini SD, Waljee AK (2014). Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis. Gastrointest Endosc, 81(3), 700-709.e3.
  42. Inadomi JM (2014). Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus. Best Pract Res Clin Gastroenterol, 29(1), 51-63.
  43. Somsouk M, Estes JD, Deleage C, Dunham RM, Albright R, Inadomi JM, Martin JN, Deeks SG, McCune JM, Hunt PW (2014). Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS, 29(1), 43-51.
  44. Park WG, Shaheen NJ, Cohen J, Pike IM, Adler DG, Inadomi JM, Laine LA, Lieb JG 2nd, Rizk MK, Sawhney MS, Wani S (2014). Quality indicators for EGD. Am J Gastroenterol, 110(1), 60-71.
  45. Singal AG, Gupta S, Lee J, Halm EA, Rutter CM, Corley D, Inadomi J (2015). Importance of determining indication for colonoscopy: implications for practice and policy original. Clin Gastroenterol Hepatol, 12(12), 1958-63.e1-3.
  46. Biggins SW, Gralla J, Dodge JL, Bambha KM, Tong S, Barn AE, Inadomi J, Terrault N, Rosen HR (2014). Survival benefit of repeat liver transplantation in the United States: a serial MELD analysis by hepatitis C status and donor risk index. Am J Transplant, 14(11), 2588-94.
  47. Gupta S, Brenner AT, Ratanawongsa N, Inadomi JM (2014). Patient trust in physician influences colorectal cancer screening in low-income patients. Am J Prev Med, 47(4), 417-23.
  48. Suzuki H, Matsuzaki J, Masaoka T, Inadomi JM (2014). Greater loss of productivity among Japanese workers with gastro-esophageal reflux disease (GERD) symptoms that persist vs resolve on medical therapy. Neurogastroenterol Motil, 26(6), 764-71.
  49. Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle CR, Miller MC, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, Feuer EJ, Inadomi JM, Hur C, Luebeck EG (2014). Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. Cancer Epidemiol Biomarkers Prev, 23(6), 997-1006.
  50. Day LW, Siao D, Inadomi JM, Somsouk M (2014). Non-physician performance of lower and upper endoscopy: a systematic review and meta-analysis. Endoscopy, 46(5), 401-10.
  51. Somsouk M, Too K, Ali M, Vittinghoff E, Yeh BM, Yee J, Monto A, Inadomi JM, Aslam R (2013). Esophageal varices on computed tomography and subsequent variceal hemorrhage. Abdom Imaging, 39(2), 251-6.
  52. Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, Lemmens VE, van Heijningen EB, Aragons N, van Ballegooijen M, Inadomi JM (2013). Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands. Am J Gastroenterol, 109(3), 336-43; quiz 335, 344.
  53. Dimagno MJ, Wamsteker EJ, Rizk RS, Spaete JP, Gupta S, Sahay T, Costanzo J, Inadomi JM, Napolitano LM, Hyzy RC, Desmond JS (2014). A combined paging alert and web-based instrument alters clinician behavior and shortens hospital length of stay in acute pancreatitis. Am J Gastroenterol, 109(3), 306-15.
  54. Rubenstein JH, Morgenstern H, Chey WD, Murray J, Scheiman JM, Schoenfeld P, Appelman HD, McMahon L, Metko V, Kellenberg J, Kalish T, Baker J, Inadomi JM (2013). Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's oesophagus. Gut, 63(2), 230-5.
  55. Rubenstein JH, Inadomi JM, Scheiman J, Schoenfeld P, Appelman H, Zhang M, Metko V, Kao JY (2013). Association between Helicobacter pylori and Barrett's esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol, 12(2), 239-45.
  56. Taylor VM, Ko LK, Hwang JH, Sin MK, Inadomi JM (2015). Gastric cancer in asian american populations: a neglected health disparity. Asian Pac J Cancer Prev, 15(24), 10565-71.
  57. Rubenstein JH, Morgenstern H, McConell D, Scheiman JM, Schoenfeld P, Appelman H, McMahon LF Jr, Kao JY, Metko V, Zhang M, Inadomi JM (2013). Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus. Gastroenterology, 145(6), 1237-44.e1-5.
  58. Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB (2013). American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-╬▒ biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology, 145(6), 1464-78.e1-5.
  59. Inadomi JM, Weinberg DS (2014). How to recognize a good guideline. Gastroenterology, 145(6), 1179-81.
  60. Day LW, Bhuket T, Inadomi JM, Yee HF (2013). Diversity of endoscopy center operations and practice variation across California's safety-net hospital system: a statewide survey. BMC Res Notes, 6, 233.
  61. Wernli KJ, Inadomi JM (2013). Anesthesia for colonoscopy: too much of a good thing? JAMA Intern Med, 173(7), 556-8.
  62. Sultan S, Falck-Ytter Y, Inadomi JM (2013). The AGA institute process for developing clinical practice guidelines part one: grading the evidence. Clin Gastroenterol Hepatol, 11(4), 329-32.
  63. Ho C, Kornfield R, Vittinghoff E, Inadomi J, Yee H, Somsouk M (2013). Late presentation of colorectal cancer in a vulnerable population. Am J Gastroenterol, 108(4), 466-70.
  64. Rubenstein JH, Morgenstern H, Appelman H, Scheiman J, Schoenfeld P, McMahon LF Jr, Metko V, Near E, Kellenberg J, Kalish T, Inadomi JM (2013). Prediction of Barrett's esophagus among men. Am J Gastroenterol, 108(3), 353-62.
  65. Ladabaum U, Brill JV, Sonnenberg A, Shaheen NJ, Inadomi J, Wilcox CM, Park WG, Hur C, Pasricha PJ (2012). How to value technological innovation: a proposal for determining relative clinical value. Gastroenterology, 144(1), 5-8.
  66. Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, Gralla J, Rosen HR, Roberts JP (2012). Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl, 18(12), 1471-8.
  67. Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM (2012). The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology, 143(3), 567-575.
  68. Inadomi JM, Vijan S, Janz NK, Fagerlin A, Thomas JP, Lin YV, Muoz R, Lau C, Somsouk M, El-Nachef N, Hayward RA (2012). Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med, 172(7), 575-82.
  69. Matsuzaki J, Suzuki H, Asakura K, Fukushima Y, Inadomi JM, Takebayashi T, Hibi T (2012). Classification of functional dyspepsia based on concomitant bowel symptoms. Neurogastroenterol Motil, 24(4), 325-e164.
  70. Fass R, Inadomi J, Han C, Mody R, ONeil J, Perez MC (2011). Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol, 10(3), 247-53.
  71. Rutter CM, Johnson E, Miglioretti DL, Mandelson MT, Inadomi J, Buist DS (2011). Adverse events after screening and follow-up colonoscopy. Cancer Causes Control, 23(2), 289-96.
  72. Day LW, Kwon A, Inadomi JM, Walter LC, Somsouk M (2011). Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc, 74(4), 885-96.
  73. Rubenstein JH, Morgenstern H, Kellenberg J, Kalish T, Donovan J, Inadomi J, McConnell D, Stojanovska J, Schoenfeld P (2011). Validation of a new physical activity questionnaire for a sedentary population. Dig Dis Sci, 56(9), 2678-87.
  74. Day LW, Cello JP, Somsouk M, Inadomi JM (2011). Prevalence of gastric cancer versus colorectal cancer in Asians with a positive fecal occult blood test. Indian J Gastroenterol, 30(5), 209-16.
  75. Buxbaum JL, Biggins SW, Bagatelos KC, Inadomi JM, Ostroff JW (2011). Inoperable pancreatic cancer patients who have prolonged survival exhibit an increased risk of cholangitis. JOP, 12(4), 377-83.
  76. Brown LM, Rogers SJ, Cello JP, Brasel KJ, Inadomi JM (2011). Cost-effective treatment of patients with symptomatic cholelithiasis and possible common bile duct stones. J Am Coll Surg, 212(6), 1049-1060.e1-7.
  77. Zheng P, Kornfield R, Olmo C, Guy J, Inadomi J, Biggins SW (2011). Reduced effectiveness of standard recruitment for deceased organ donor registration: the need for population-specific recruitment materials. Dig Dis Sci, 56(5), 1535-41.
  78. Limoges-Gonzalez M, Mann NS, Al-Juburi A, Tseng D, Inadomi J, Rossaro L (2011). Comparisons of screening colonoscopy performed by a nurse practitioner and gastroenterologists: a single-center randomized controlled trial. Gastroenterol Nurs, 34(3), 210-6.
  79. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ, American Gastroenterological Association (2011). American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology, 140(3), e18-52; quiz e13.
  80. American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology, 140(3), 1084-91.
  81. Rubenstein JH, Scheiman JM, Sadeghi S, Whiteman D, Inadomi JM (2010). Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol, 106(2), 254-60.
  82. Somsouk M, Kornfield R, Vittinghoff E, Inadomi JM, Biggins SW (2011). Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transpl, 17(2), 129-36.
  83. Sewell JL, Inadomi JM, Yee HF Jr (2010). Race and inflammatory bowel disease in an urban healthcare system. Dig Dis Sci, 55(12), 3479-87.
  84. Inadomi JM, Gunnarsson CL, Rizzo JA, Fang H (2010). Projected increased growth rate of anesthesia professional-delivered sedation for colonoscopy and EGD in the United States: 2009 to 2015. Gastrointest Endosc, 72(3), 580-6.
  85. Heidelbaugh JJ, Goldberg KL, Inadomi JM (2011). Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care, 16(9), e228-34.
  86. Inadomi J (2010). Issues Related to BID Dosing of PPIs. Gastroenterol Hepatol (N Y), 6(6), 369-70.
  87. Menees SB, Inadomi J, Elta G, Korsnes S, Punch M, Aldrich L (2010). Colorectal cancer screening compliance and contemplation in gynecology patients. J Womens Health (Larchmt), 19(5), 911-7.
  88. Sewell JL, Yee HF Jr, Inadomi JM (2009). Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis, 16(2), 204-7.
  89. Dassopoulos T, Inadomi JM, Lewis JD, Allen JI (2009). The development of clinical guidelines by the American Gastroenterological Association. Gastroenterology, 138(2), 417-8.
  90. Lambert R, Kudo SE, Vieth M, Allen JI, Fujii H, Fujii T, Kashida H, Matsuda T, Mori M, Saito H, Shimoda T, Tanaka S, Watanabe H, Sung JJ, Feld AD, Inadomi JM, OBrien MJ, Lieberman DA, Ransohoff DF, Soetikno RM, Zauber A, Teixeira CR, Rey JF, Jaramillo E, Rubio CA, Van Gossum A, Jung M, Jass JR, Triadafilopoulos G (2009). Pragmatic classification of superficial neoplastic colorectal lesions. Gastrointest Endosc, 70(6), 1182-99.
  91. Biggins SW, Bambha K, Terrault N, Inadomi J, Roberts JP, Bass N (2009). Transplant tourism to China: the impact on domestic patient-care decisions. Clin Transplant, 23(6), 831-8.
  92. Guy J, Somsouk M, Shiboski S, Kerlan R, Inadomi JM, Biggins SW (2009). New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt. Clin Gastroenterol Hepatol, 7(11), 1236-40.
  93. Somsouk M, Guy J, Biggins SW, Vittinghoff E, Kohn MA, Inadomi JM (2009). Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Aliment Pharmacol Ther, 30(7), 741-8.
  94. Sewell JL, Kushel MB, Inadomi JM, Yee HF Jr (2009). Non-English speakers attend gastroenterology clinic appointments at higher rates than English speakers in a vulnerable patient population. J Clin Gastroenterol, 43(7), 652-60.
  95. Suzuki H, Inadomi JM, Hibi T (2009). Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterol Motil, 21(7), 688-96.
  96. Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ (2009). A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology, 136(7), 2101-2114.e1-6.
  97. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT (2009). National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology, 49(5 Suppl), S4-S12.
  98. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM, American College of Gastroenterology (2009). American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol, 104(3), 739-50.
  99. Heidelbaugh JJ, Goldberg KL, Inadomi JM (2009). Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol, 104 Suppl 2, S27-32.
  100. Inadomi JM (2009). Surveillance in Barrett's esophagus: a failed premise. Keio J Med, 58(1), 12-8.
  101. Inadomi JM (2009). Updates in colorectal cancer screening. F1000 Med Rep, 1.
  102. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT (2009). National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med, 150(2), 104-10.
  103. Inadomi JM (2009). Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence. J Gastroenterol Hepatol, 23 Suppl 2, S198-204.
  104. Rubenstein JH, Sonnenberg A, Davis J, McMahon L, Inadomi JM (2008). Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc, 68(5), 849-55.
  105. Elmunzer BJ, Young SD, Inadomi JM, Schoenfeld P, Laine L (2008). Systematic review of the predictors of recurrent hemorrhage after endoscopic hemostatic therapy for bleeding peptic ulcers. Am J Gastroenterol, 103(10), 2625-32; quiz 2633.
  106. Kudo Se, Lambert R, Allen JI, Fujii H, Fujii T, Kashida H, Matsuda T, Mori M, Saito H, Shimoda T, Tanaka S, Watanabe H, Sung JJ, Feld AD, Inadomi JM, OBrien MJ, Lieberman DA, Ransohoff DF, Soetikno RM, Triadafilopoulos G, Zauber A, Teixeira CR, Rey JF, Jaramillo E, Rubio CA, Van Gossum A, Jung M, Vieth M, Jass JR, Hurlstone PD (2008). Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc, 68(4 Suppl), S3-47.
  107. Rubenstein JH, Dahlkemper A, Kao JY, Zhang M, Morgenstern H, McMahon L, Inadomi JM (2008). A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol, 103(6), 1358-64.
  108. Somsouk M, Gralnek IM, Inadomi JM (2008). Management of obscure occult gastrointestinal bleeding: a cost-minimization analysis. Clin Gastroenterol Hepatol, 6(6), 661-70.
  109. Somsouk M, Langfield DE, Inadomi JM, Yee HF Jr (2007). A cost-identification analysis of screening and surveillance of hepatitis C infection in a prospective cohort of dialysis patients. Dig Dis Sci, 53(4), 1093-9.
  110. Inadomi JM (2008). Fear of loss, not promise of gain, drives practice patterns in Barrett's esophagus. Gastroenterology, 134(4), 1258-60; discussion 1260.
  111. Inadomi JM, Somsouk MA (2007). Will virtual colonoscopy replace optical colonoscopy for colorectal cancer screening? Gastroenterology, 133(4), 1384-5; discussion 1385-6.
  112. Rubenstein JH, Nojkov B, Korsnes S, Adlis SA, Shaw MJ, Weinman B, Inadomi JM, Saad R, Chey WD (2007). Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther, 26(3), 443-52.
  113. Cohen LB, Delegge MH, Aisenberg J, Brill JV, Inadomi JM, Kochman ML, Piorkowski JD Jr, AGA Institute (2007). AGA Institute review of endoscopic sedation. Gastroenterology, 133(2), 675-701.
  114. Elmunzer BJ, Inadomi JM, Elta GH (2007). Risk stratification in upper gastrointestinal bleeding. J Clin Gastroenterol, 41(6), 559-63.
  115. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, OHare AM (2007). Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med, 167(12), 1271-6.
  116. Inadomi JM, Somsouk MA (2007). Proton pump inhibitors and hip fracture: cause for alarm? Gastroenterology, 132(5), 2063-5; discussion 2065.
  117. Metz DC, Inadomi JM, Howden CW, van Zanten SJ, Bytzer P (2006). On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol, 102(3), 642-53.
  118. Rubenstein JH, Inadomi JM, Brill JV, Eisen GM (2007). Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol, 5(3), 312-8.
  119. Vijan S, Hwang I, Inadomi J, Wong RK, Choi JR, Napierkowski J, Koff JM, Pickhardt PJ (2006). The cost-effectiveness of CT colonography in screening for colorectal neoplasia. Am J Gastroenterol, 102(2), 380-90.
  120. Inadomi JM (2007). Patients prefer conventional to virtual colonoscopy. Gastroenterology, 132(2), 809-11; discussion 811.
  121. Inadomi JM (2006). Implementing a research project: the nitty gritty. Gastrointest Endosc, 64(6 Suppl), S7-10.
  122. Heidelbaugh JJ, Inadomi JM (2006). Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol, 101(10), 2200-5.
  123. Rubenstein JH, Inadomi JM (2006). Evidence based medicine (EBM) in practice: applying results of cost-effectiveness analyses. Am J Gastroenterol, 101(6), 1169-71.
  124. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP (2006). Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 23(10), 1473-7.
  125. Chey WD, Eswaren S, Howden CW, Inadomi JM, Fendrick AM, Scheiman JM (2006). Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey. Aliment Pharmacol Ther, 23(5), 655-68.
  126. Rubenstein JH, Inadomi JM (2006). Defining a clinically significant adverse impact of diagnosing Barrett's esophagus. J Clin Gastroenterol, 40(2), 109-15.
  127. Menees SB, Inadomi JM, Korsnes S, Elta GH (2005). Women patients' preference for women physicians is a barrier to colon cancer screening. Gastrointest Endosc, 62(2), 219-23.
  128. Rubenstein JH, Davis J, Marrero JA, Inadomi JM (2005). Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Aliment Pharmacol Ther, 22(3), 267-71.
  129. Rubenstein JH, Vakil N, Inadomi JM (2005). The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol Ther, 22(2), 135-46.
  130. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW (2005). Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol, 100(6), 1237-42.
  131. Inadomi JM, Fendrick AM (2005). PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol, 3(3), 208-15.
  132. Shaheen NJ, Inadomi JM, Overholt BF, Sharma P (2004). What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut, 53(12), 1736-44.
  133. Vijan S, Inadomi J, Hayward RA, Hofer TP, Fendrick AM (2004). Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the United States. Aliment Pharmacol Ther, 20(5), 507-15.
  134. Rubenstein JH, Eisen GM, Inadomi JM (2004). A cost-utility analysis of secondary prophylaxis for variceal hemorrhage. Am J Gastroenterol, 99(7), 1274-88.
  135. Inadomi JM (2004). Decision analysis and economic modelling: a primer. Eur J Gastroenterol Hepatol, 16(6), 535-42.
  136. Inadomi JM, McIntyre L, Bernard L, Fendrick AM (2003). Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol, 98(9), 1940-4.
  137. Inadomi JM, Sonnenberg A (2004). An evidence-based medicine approach to economic studies: assessing the cost-effectiveness of competing strategies for colorectal cancer screening. Clin Gastroenterol Hepatol, 1(5), 404-13.
  138. Cram P, Fendrick AM, Inadomi J, Cowen ME, Carpenter D, Vijan S (2003). The impact of a celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect. Arch Intern Med, 163(13), 1601-5.
  139. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N (2003). Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med, 138(3), 176-86.
  140. Rhee J, Scheiman J, Inadomi J (2003). "Spontaneous" passage of a pancreatic duct stone. Gastrointest Endosc, 57(2), 278-80.
  141. Inadomi JM (2003). Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis. Scand J Gastroenterol Suppl, (237), 17-21.
  142. Inadomi JM (2005). Update on the cost-effectiveness of screening for colorectal neoplasia. Curr Opin Gastroenterol, 19(1), 44-50.
  143. El-Serag HB, Graham DY, Richardson P, Inadomi JM (2002). Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med, 162(18), 2105-10.
  144. Inadomi JM (2002). On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations. Pharmacoeconomics, 20(9), 565-76.
  145. Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM, Swanson KM, Sonnenberg A (2001). Step-down management of gastroesophageal reflux disease. Gastroenterology, 121(5), 1095-100.
  146. Gorelick AB, Inadomi JM, Barnett JL (2001). Unsedated small-caliber esophagogastroduodenoscopy (EGD): less expensive and less time-consuming than conventional EGD. J Clin Gastroenterol, 33(3), 210-4.
  147. El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM (2001). Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol, 96(4), 979-83.
  148. Inadomi JM, Kapur S, Kinkhabwala M, Cello JP (2001). The laparoscopic evaluation of ascites. Gastrointest Endosc Clin N Am, 11(1), 79-91.
  149. Sonnenberg A, Delc F, Inadomi JM (2000). Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med, 133(8), 573-84.
  150. Inadomi JM, Sonnenberg A (2000). The impact of colorectal cancer screening on life expectancy. Gastrointest Endosc, 51(5), 517-23.
  151. El-Serag HB, Inadomi JM, Kowdley KV (2000). Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med, 132(4), 261-9.
  152. El-Serag HB, Sonnenberg A, Jamal MM, Inadomi JM, Crooks LA, Feddersen RM (1999). Corpus gastritis is protective against reflux oesophagitis. Gut, 45(2), 181-5.
  153. Sonnenberg A, Inadomi JM, Becker LA (1999). Economic analysis of step-wise treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 13(8), 1003-13.
  154. Sonnenberg A, Inadomi JM, Bauerfeind P (1999). Reliability block diagrams to model disease management. Med Decis Making, 19(2), 180-5.
  155. Sonnenberg A, Inadomi JM (1999). Reliability block diagrams to model the management of colorectal cancer. Dig Dis Sci, 44(2), 314-21.
  156. Sonnenberg A, Inadomi JM (1999). Economic perspectives in the management of Helicobacter pylori infections. Curr Top Microbiol Immunol, 241, 237-60.
  157. Inadomi JM, Sonnenberg A (1998). The impact of peptic ulcer disease and infection with Helicobacter pylori on life expectancy. Am J Gastroenterol, 93(8), 1286-90.
  158. Sonnenberg A, Inadomi JM (1998). Review article: Medical decision models of Helicobacter pylori therapy to prevent gastric cancer. Aliment Pharmacol Ther, 12 Suppl 1, 111-21.
  159. Inadomi J, Sonnenberg A (1997). Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology, 113(4), 1289-94.
  160. Inadomi J, Cello JP, Koch J (1996). Ultrasonographic determination of ascitic volume. Hepatology, 24(3), 549-51.
  161. Inadomi J, Koch J, Cello JP (1995). Long-term follow-up of endoscopic treatment for bleeding gastric and duodenal ulcers. Am J Gastroenterol, 90(7), 1065-8.
  162. Miegel RE, Walker PS, Nelson PC, Inadomi J, Needelman L, Maxine M (1986). A compliant interface for total knee arthroplasty. J Orthop Res, 4(4), 486-93.

Conference Proceedings

  1. Wani S, Muthusamy VR, Shaheen NJ, Yadlapati R, Wilson R, Abrams JA, Bergman J, Chak A, Chang K, Das A, Dumot J, Edmundowicz SA, Eisen G, Falk GW, Fennerty MB, Gerson L, Ginsberg GG, Grande D, Hall M, Harnke B, Inadomi J, Jankowski J, Lightdale CJ, Makker J, Odze RD, Pech O, Sampliner RE, Spechler S, Triadafilopoulos G, Wallace MB, Wang K, Waxman I, Komanduri S (2017). Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Gastrointest Endosc, United States, 86(1), 1-17.e3.
  2. Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, Sanders S, Gay L, Pech O, Longcroft-Wheaton G, Romero Y, Inadomi J, Tack J, Corley DA, Manner H, Green S, Al Dulaimi D, Ali H, Allum B, Anderson M, Curtis H, Falk G, Fennerty MB, Fullarton G, Krishnadath K, Meltzer SJ, Armstrong D, Ganz R, Cengia G, Going JJ, Goldblum J, Gordon C, Grabsch H, Haigh C, Hongo M, Johnston D, Forbes-Young R, Kay E, Kaye P, Lerut T, Lovat LB, Lundell L, Mairs P, Shimoda T, Spechler S, Sontag S, Malfertheiner P, Murray I, Nanji M, Poller D, Ragunath K, Regula J, Cestari R, Shepherd N, Singh R, Stein HJ, Talley NJ, Galmiche JP, Tham TC, Watson P, Yerian L, Rugge M, Rice TW, Hart J, Gittens S, Hewin D, Hochberger J, Kahrilas P, Preston S, Sampliner R, Sharma P, Stuart R, Wang K, Waxman I, Abley C, Loft D, Penman I, Shaheen NJ, Chak A, Davies G, Dunn L, Falck-Ytter Y, Decaestecker J, Bhandari P, Ell C, Griffin SM, Attwood S, Barr H, Allen J, Ferguson MK, Moayyedi P, Jankowski JA (2012). Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology, United States, 143(2), 336-46.
  3. Rimola A, Garca-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM (2000). Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol, Netherlands, 32(1), 142-53.

Editorial

  1. Inadomi JM (2020). What's App with GERD? Gastroenterology.
  2. Bibbins-Domingo K, Inadomi J (2018). Why "More Research Is Needed," Despite Overall Certainty: Women and Colorectal Cancer Screening. Ann Intern Med, 168(11), 824-825.
  3. Friedman LS, Inadomi JM, Kalloo AM, Katzka DA, Kim LS, Koch J, Lieberman D, Lichtenstein GR, Lim JK, Pandolfino JE, Shin AS, Siedler MR (2016). Introduction of Clinical Practice Update Committee Articles. Clin Gastroenterol Hepatol, 15(1), 4.
  4. Inadomi JM (2016). Colorectal Cancer Screening: Which Test Is Best? JAMA Oncol, 2(8), 1001-3.
  5. Inadomi JM (2012). Is 325 mg of prevention worth a pound of cure? Gastroenterology, 143(4), 885-7.
  6. Inadomi JM (2012). Why you should care about screening flexible sigmoidoscopy. N Engl J Med, 366(25), 2421-2.
  7. Inadomi JM (2011). Time to burn? Endoscopic ablation for Barrett's esophagus. Gastroenterology, 141(2), 417-9.
  8. Inadomi J (2010). Editorial: Interval cancers after colonoscopy: the importance of training. Am J Gastroenterol, 105(12), 2597-8.
  9. Inadomi JM (2008). In search of quality colonoscopy. Gastroenterology, 135(6), 1845-7.
  10. Inadomi JM, Terdiman J (2006). Exploring utilities and outcomes with infliximab therapy. Clin Gastroenterol Hepatol, 4(8), 976-8.
  11. Rubenstein JH, Inadomi JM (2005). Dysphagia drives doctors to diagnose a disease: pitfalls in interpreting observational studies. Gastrointest Endosc, 61(7), 809-11.
  12. Rubenstein JH, Inadomi JM (2003). Empiric beta-blockers for the prophylaxis of variceal hemorrhage: cost effective or clinically applicable? Hepatology, 37(2), 249-52.

Letter

  1. Inadomi JM (2017). Screening for Colorectal Neoplasia. [Letter to the editor]. N Engl J Med, 376(16), 1599-1600.
  2. Rubenstein JH, Inadomi JM (2009). Potential for lead-time and length-time biases in outcomes in esophageal adenocarcinoma. [Letter to the editor]. Am J Gastroenterol, 104(12), 3106-7; author reply 3107-8.

Other

  1. Chiba N, Gralnek IM, Moayyedi P, Provenzale D, Inadomi JM, Willan AR, Briggs AH, Kim WR (2004). A glossary of economic terms. Eur J Gastroenterol Hepatol (16(6), pp. 563-5). England.